Video Update

The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year continued. Despite the clearly risk-off sentiment in the broader investment community, the companies in BB Biotech's portfolio reported many important R&D milestones, including late-stage clinical trial results. Learn more in the video update with Dr. Daniel Koller, Head Investment Team, on the occasion of BB Biotech AG's half-year results 2022.